[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypopituitarism\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypopituitarism":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,77,105,130],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100636655","early-phase-1-identifying-oxytocin-deficiency-in-pediatric-patients-with-pituitary-disease-100636655",false,"NCT07568509","Identifying Oxytocin Deficiency in Pediatric Patients With Pituitary Disease","Identifying a Provocation Test for Diagnosis of Oxytocin Deficiency in Youth With Hypopituitarism","Pedi-EVOLVE","Inclusion criteria (participants with AVP-D):\n\n* AVP-D diagnosed in clinic using standard of care diagnostic tools;\n* Stable pituitary hormone replacement (no change in dose of hormone replacement in six weeks prior to baseline);\n* If on estrogen\u002Fprogestin, female participants agree to stop for at least 6 weeks prior to Main study visits;\n* English language proficiency.\n\nInclusion criteria (participants with hypopituitary disease):\n\n* Hypopituitary disease diagnosis;\n* If receiving pituitary hormone replacement, no change in dose in six weeks prior to baseline);\n* If on estrogen\u002Fprogestin, participants agree to stop for at least 6 weeks prior to Main study visits;\n* English language proficiency.\n\nExclusion criteria (all participants):\n\n* History of pulmonary embolism or unprovoked deep venous thrombosis;\n* History of breast\u002Fendometrial cancer as well as current therapies on estrogen modulators\u002Fblockers (i.e., tamoxifen, raloxifene, aromatase inhibitors);\n* History of stroke, transient ischemic attack, myocardial infarction, angina pectoris, or peripheral arterial disease;\n* Pregnancy or breastfeeding within the last 8 weeks;\n* Medication changes within 2 weeks of enrollment or within 5 half-lives of the respective medication;\n* History of stage 3 chronic kidney disease or cirrhosis;\n* Any significant illness or condition that the investigator determines could interfere with study participation, data collection or safety;\n* Active tobacco smoking or nicotine patch use;\n* Psychosis or active suicidality.","ALL","7 Years","21 Years",{"count":21,"type":22},20,"ESTIMATED","INTERVENTIONAL",[25],"EARLY_PHASE1","An open-labeled, interventional pilot trial, 10 youth with AVP-D and 10 PD matched for age, sex, and BMI will be recruited from Pediatric Endocrinology and Neuroendocrinology at Massachusetts General Hospital and in the community. This study tests the hypothesis that oral estrogen\u002Fprogestin will stimulate endogenous oxytocin release in control subjects. Eligible participants will receive two tablets in a single administration containing a total of 1 mg of norethindrone acetate 70 mcg of ethinyl estradiol. Sampling for blood and saliva will take place at baseline and approximately 24 hours following study drug administration. Neuropsychological assessment (anxiety, mood and emotion regulation; impulse control; aberrant eating behaviors; social cognition and functioning; quality of life) will be assessed at baseline to characterize the study population.",[28,29,30,31],"Arginine Vasopressin Deficiency","Oxytocin Deficiency","Pediatric Disease","Hypopituitarism","RECRUITING","2026-05-12",{"date":35,"type":36},"2026-05-15","ACTUAL",{"date":38,"type":22},"2026-05",{"date":40,"type":22},"2027-04",{"name":42,"class":43},"Massachusetts General Hospital","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":58,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":44},"100603957","sleep-disorders-in-hypothalamic-and-pituitary-damage-100603957","NCT07143266","Sleep Disorders in Hypothalamic and Pituitary Damage","Multidisciplinary Approach to Elucidate the Pathophysiology of Sleep Disorders in Patients With Hypothalamic and Pituitary Damage","SDHPD","Inclusion Criteria:\n\n* Patients with hypothalamic-pituitary dysfunction (HPD) with at least one pituitary hormone deficiency and at least one clinical sign of hypothalamic damage (e.g., arginine-vasopressin deficiency (AVP-D) and\u002For severe obesity and\u002For hyperphagia; MRI suggestive of hypothalamic damage; traumatic brain injury; radiotherapy in the sellar region and\u002For brain tumors affecting the hypothalamus).\n* Healthy controls matched for BMI, age, and sex.\n\nExclusion Criteria:\n\n* Poor control of hormonal deficiencies in the previous 6 months.\n* Use of new psychoactive drugs in the last 3 months or occasional use.\n* Clinically significant liver, lung, kidney, and cardiovascular disease.\n* Any neurological condition affecting brain function (stroke, dementia, uncontrolled epilepsy with recent seizures).\n* Uncontrolled diabetes mellitus.\n* Active psychosis.\n* Ophthalmology: total blindness, Glaucoma, uveitis, visual acuity \\\u003C0.6, or eye surgery in the previous 6 months.\n* Any acute illness that the investigator determines may interfere with study participation or safety.\n* Pregnancy or breastfeeding.\n* Patients who refuse or are unable to provide written informed consent.\n* In controls: presence of brain or pituitary tumor, radiation involving the hypothalamus or pituitary, and history of hypopituitarism.",true,"18 Years","70 Years",{"count":57,"type":22},60,"3 Months","OBSERVATIONAL","Hypothalamus has a key role in multiple vital functions, including regulation of sleep-wake cycles. Oxytocin (OT), a neurohormone synthetized in the hypothalamus, has a wide range of physiological functions, including a putative role in improving sleep quality. Hypothalamic and pituitary damage (HPD) is associated with a clinically relevant OT deficient state and multiple and severe comorbidities including poor sleep quality, that have a well-known negative impact on general health and quality of life (QoL). Several factors may coexist in the pathophysiology of sleep disorders (SD) in HPD and SD might be a keystone in the persistence of some of the comorbidities observed in HPD. Therefore, appropriate identification and understanding of the mechanisms contributing to SD in HPD is mandatory to choose adequate preventive strategies and treatment. This project is aimed to (1) identify the prevalence of SD in HPD, (2) to determine OT role in sleep quality and (3) to identify potential mechanisms and mediators of sleep quality and their associations with clinical outcomes in patients with HPD with the ultimate goal of identifying preventive and therapeutic targets. We will use a controlled cross-sectional design of patients with HPD and sex-, BMI-, age- matched controls and an innovative cross-disciplinary approach bridging neuroendocrinology, psychology, neurophysiology, neuroimaging, nuclear medicine and neuroophthalmology disciplines to learn about the prevalence of SD in HPD and to disentangle the underpinning mechanisms behind SDs in HPD. The results of this project will be an extremely important step towards optimizing therapy for patients with HPD who have higher mortality and poor QoL despite appropriate hormone replacement therapy.",[31,62,63,29],"Sleep Wake Disorders","Hypothalamic Diseases",[65,66,31,67],"Sleep Disorder","Oxytocin deficiency","Hypothalamic damage","2025-11-14",{"date":70,"type":36},"2025-11-18",{"date":72,"type":36},"2025-09-01",{"date":74,"type":22},"2027-12",{"name":76,"class":43},"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":104},"100515360","pituitary-function-after-recovery-from-septic-shock-among-icu-survivors-100515360","NCT05990491","Pituitary Function After Recovery From Septic Shock Among ICU Survivors","Pituitary Function After Recovery From Septic Shock Among ICU Survivors: A Prospective, Observational Study","Inclusion Criteria:\n\nSeptic shock group:\n\n* Patients 18-80 years of age who meet the definition of septic shock.\n* Vasopressor requirement should be maintained for a period \\> 24 hours and should require ICU stay for a duration of \\> 7 days.\n* Patient should recover from shock and be planned for discharge from the ICU\n\nNon-septic shock group\n\n* Patients 18-80 years of age who planned for discharge from the ICU.with stay for a duration of \\>7 days.\n* Also, they should not have received vasopressor for.a period of \\>24 hours\n\nExclusion Criteria:\n\n* Patients who refuse to provide consent.\n* Age \\\u003C18 years or \\> 80 years of age.\n* Pregnancy or immediate post-partum (\\\u003C 6 months post-delivery).\n* Chronic kidney disease (Stage 5), chronic liver disease (CHILD B or C), severe Chronic obstructive pulmonary disease, Chronic heart failure.\n* Patients with pre-existing hypopituitarism on replacement.\n* Past history of severe post-partum hemorrhage requiring blood transfusion, traumatic brain injury, subarachnoid hemorrhage, pituitary tumor\u002Fsurgery, snake bite envenomation and meningo-encephalitis.\n* Patients who have been on \\> 5 mg prednisolone equivalent for a period of more than 2 weeks at any time in the previous 6 months before admission.","80 Years",{"count":86,"type":22},90,"Prolonged circulatory shock is associated with marked disturbances in vascular supply to the brain, and endothelial dysfunction which can lead to disseminated intravascular coagulation and microvascular thrombosis. Pituitary dysfunction is documented following post-partum hemorrhage, traumatic brain injury and subarachnoid hemorrhage, which also affect blood flow to the pituitary. However, there are no studies assessing pituitary function in the aftermath of recovery from shock. This will be a prospective observational study of patients admitted in Critical Care Medicine (CCM) ICU who have recovered from prolonged septic shock (Lasting for a period of \\> 24 hours). Blood samples of the participants will be estimated at the time of discharge from the ICU and at 6 months post discharge. Investigators will estimate fasting serum cortisol, TSH, Free T4, Testosterone (in males), Oestrogen (in females), LH, FSH, Prolactin, IGF-1 and plasma ACTH in all participants at both time points (at the time of ICU discharge and at 6-months follow-up). Participants who have borderline serum cortisol values (138-400 nmol\u002Fl) will be subjected to 250ug ACTH stimulation test. Expected outcome of the proposed study is to know proportion of patients having pituitary hormone axis dysfunction. Investigators will also look for pituitary dysfunction persist or revert, or there are new onset dysfunction at 6 month follow up. This would have major implications in the follow up and management of ICU survivors.",[89,90,31],"Shock, Septic","Pituitary Dysfunction",[92,93,31],"Septic shock","Post intensive care syndrome","2024-10-09",{"date":96,"type":36},"2024-10-15",{"date":98,"type":36},"2023-08-28",{"date":100,"type":22},"2025-08",{"name":102,"class":103},"Sanjay Gandhi Postgraduate Institute of Medical Sciences","OTHER_GOV",2,{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":4},"100541207","neuroendocrine-mechanisms-in-adiposity-an-integrated-approach-to-the-characterization-of-potential-pharmacological-novel-targets-based-on-experimental-and-clinical-models-100541207","NCT06326853","Neuroendocrine Mechanisms in Adiposity: An Integrated Approach to the Characterization of Potential Pharmacological Novel Targets Based on Experimental and Clinical Models","Inclusion Criteria:\n\nObese patients affected and not by hypothalamic-pituitary diseases\n\nExclusion Criteria:\n\n1. Minor subjects;\n2. Pregnant and\u002For breastfeeding women;\n3. Patients suffering from states of primary and\u002For acquired immunodeficiencies, and\u002For serious impairment of general clinical conditions (e.g. metastatic neoplasms; immunosuppressive therapies; worsening\u002Freacerbated\u002Fcompensated chronic pathologies);\n4. Patients unable to understand and sign the Informed Consent.",{"count":112,"type":22},200,"The goal of this observational study is to evaluate, retrospectively and prospectively, the effect of different hormonal and neuropeptide dysfunctions on the body composition of patients suffering from hypothalamic-pituitary pathologies, and to evaluate the potential beneficial effect of surgical and medical treatments with agonists and antagonists of hypothalamic neuropeptides, currently available, on the development and treatment of adiposity and negative cross-talk between adiposity and muscle\u002Fbone tissue",[115,116,117,118,119,31],"Endocrine Disorders","Adiposity","Pituitary Adenoma","Cushing Syndrome","Acromegaly","NOT_YET_RECRUITING","2024-06-10",{"date":123,"type":36},"2024-06-11",{"date":125,"type":22},"2024-07",{"date":127,"type":22},"2026-12",{"name":129,"class":43},"IRCCS San Raffaele",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":137,"minAge":54,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":23,"phases":141,"briefSummary":143,"conditions":144,"keywords":150,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":44},"100371853","phase-2-growth-hormone-replacement-therapy-for-retried-professional-football-players-100371853","NCT04121780","Growth Hormone Replacement Therapy for Retried Professional Football Players","Interventional Study of Growth Hormone Replacement Therapy in Retired Professional Football Players With Growth Hormone Deficiency","Inclusion Criteria:\n\n* The subject is willing to provide a signed and dated informed consent indicating that he understands the purpose and procedures required for the study and is willing to participate in the study.\n* Former NFL player\n* At least one year since retirement from football\n* Less than 76 years of age\n* Diagnosis of GHD on clinical grounds by a neurologist and an endocrinologist GHD\n\nExclusion Criteria:\n\n* History of pre-existing brain disease other than concussion or TBI\n* History of a premorbid disabling condition that interferes with outcome assessments\n* Contraindication to GH therapy\n* Type I and II Diabetes mellitus\n* Active malignant disease\n* Acute critical illness, heart failure, or acute respiratory failure\n* Subjects who are deficient in cortisol, testosterone or thyroid at screening will be excluded until hormone abnormalities have been corrected.","MALE","76 Years",{"count":140,"type":22},42,[142],"PHASE2","This is a randomized, double-blind, placebo-controlled, parallel-group trial with an open-label extension to evaluate the efficacy of growth hormone (GH) on cognitive functions of retired professional football players with growth hormone deficiency (GHD).",[145,146,147,148,31,149],"TBI (Traumatic Brain Injury)","Concussion, Brain","Sport Injury","Anterior Pituitary Hyposecretion Syndrome","Growth Hormone Deficiency",[151,152,153,154,155],"TBI","GHD","Growth Hormone","Norditropin Flexpro","cognition disorders","2023-02-06",{"date":158,"type":36},"2023-02-08",{"date":160,"type":36},"2019-10-08",{"date":162,"type":22},"2026-09",{"name":164,"class":43},"Center for Neurological Studies"]